{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:33:22Z","timestamp":1787002402986,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/bmt.2016.239","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T09:46:43Z","timestamp":1474278403000},"page":"238-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT"],"prefix":"10.1038","volume":"52","author":[{"given":"S","family":"Eder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Santarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"A","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ALWP of the EBMT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,19]]},"reference":[{"key":"BFbmt2016239_CR1","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1056\/NEJMp078166","volume":"357","author":"FR Appelbaum","year":"2007","unstructured":"Appelbaum FR . Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357: 1472\u20131475.","journal-title":"N Engl J Med"},{"key":"BFbmt2016239_CR2","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1038\/bcj.2011.14","volume":"1","author":"B Mohty","year":"2011","unstructured":"Mohty B, Mohty M . Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011; 1: e16.","journal-title":"Blood Cancer J"},{"key":"BFbmt2016239_CR3","first-page":"911","volume":"17","author":"N Kamani","year":"1996","unstructured":"Kamani N, August CS, Bunin N, Leahey A, Bayever E, Goldwein J et al. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 1996; 17: 911\u2013916.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR4","first-page":"157","volume":"17","author":"JD Bitran","year":"1996","unstructured":"Bitran JD, Samuels B, Klein L, Hanauer S, Johnson L, Martinec J et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996; 17: 157\u2013162.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR5","first-page":"2340","volume":"51","author":"SF Ng","year":"1991","unstructured":"Ng SF, Waxman DJ . N,N\u2032,N\u2032\u2032-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. Cancer Res 1991; 51: 2340\u20132345.","journal-title":"Cancer Res"},{"key":"BFbmt2016239_CR6","first-page":"1605","volume":"60","author":"NM Emanuel","year":"1976","unstructured":"Emanuel NM, Konovalova NP, Djachkovskaya RF . Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thiotepa analogs. Cancer Treat Rep 1976; 60: 1605\u20131609.","journal-title":"Cancer Treat Rep"},{"key":"BFbmt2016239_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.bmt.1701103","volume":"21","author":"JD Down","year":"1998","unstructured":"Down JD, Westerhof GR, Boudewijn A, Setroikromo R, Ploemacher RE . Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transplant 1998; 21: 327\u2013330.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR8","first-page":"736","volume":"49","author":"RL Heideman","year":"1989","unstructured":"Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736\u2013741.","journal-title":"Cancer Res"},{"key":"BFbmt2016239_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bmt.1704353","volume":"33","author":"Y Nieto","year":"2004","unstructured":"Nieto Y, Vaughan WP . Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004; 33: 259\u2013269.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR10","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood.V89.11.3951","volume":"89","author":"A Nagler","year":"1997","unstructured":"Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S . Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997; 89: 3951\u20133959.","journal-title":"Blood"},{"key":"BFbmt2016239_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood.V88.1.353.353","volume":"88","author":"A Bacigalupo","year":"1996","unstructured":"Bacigalupo A, Van Lint MT, Valbonesi M, Lercari G, Carlier P, Lamparelli T et al. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood 1996; 88: 353\u2013357.","journal-title":"Blood"},{"key":"BFbmt2016239_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0145-2126(99)00112-5","volume":"23","author":"F Rosales","year":"1999","unstructured":"Rosales F, Naparstek E, Varadi G, Or R, Slavin S, Nagler A . The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. Leuk Res 1999; 23: 947\u2013952.","journal-title":"Leuk Res"},{"key":"BFbmt2016239_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1365-2141.2000.02123.x","volume":"109","author":"AM Raiola","year":"2000","unstructured":"Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Mordini N, Berisso G et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000; 109: 716\u2013721.","journal-title":"Br J Haematol"},{"key":"BFbmt2016239_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1182\/blood.V99.1.75","volume":"99","author":"P Corradini","year":"2002","unstructured":"Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75\u201382.","journal-title":"Blood"},{"key":"BFbmt2016239_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/sj.bmt.1704717","volume":"34","author":"EP Alessandrino","year":"2004","unstructured":"Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D et al. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplant 2004; 34: 1039\u20131045.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/sj.bmt.1705863","volume":"40","author":"A Bacigalupo","year":"2007","unstructured":"Bacigalupo A, Raiola AM, Lamparelli T, Gualandi F, Occhini D, Bregante S et al. Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up. Bone Marrow Transplant 2007; 40: 1091\u20131093.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/sj.bmt.1702719","volume":"26","author":"T Lamparelli","year":"2000","unstructured":"Lamparelli T, van Lint MT, Gualandi F, Raiola AM, Barbanti M, Sacchi N et al. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Bone Marrow Transplant 2000; 26: 1305\u20131311.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbmt.2009.09.001","volume":"16","author":"J Sanz","year":"2010","unstructured":"Sanz J, Sanz MA, Saavedra S, Lorenzo I, Montesinos P, Senent L et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16: 86\u201394.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016239_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/bmt.2012.13","volume":"47","author":"J Sanz","year":"2012","unstructured":"Sanz J, Boluda JC, Mart\u00edn C, Gonz\u00e1lez M, Ferr\u00e1 C, Serrano D et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012; 47: 1287\u20131293.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/leu.2013.259","volume":"28","author":"A Ruggeri","year":"2014","unstructured":"Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 2014; 28: 779\u2013786.","journal-title":"Leukemia"},{"key":"BFbmt2016239_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367\u2013369.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016239_CR22","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJM200106143442402","volume":"344","author":"MJ Laughlin","year":"2001","unstructured":"Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815\u20131822.","journal-title":"N Engl J Med"},{"key":"BFbmt2016239_CR23","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016239_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED . Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116\u2013122.","journal-title":"Hepatology"},{"key":"BFbmt2016239_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157\u2013168.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016239_CR27","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, D\u00edaz-Bey\u00e1 M, Rosi\u00f1ol L, Mart\u00ednez C, Fern\u00e1ndez-Avil\u00e9s F, Rovira M . The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011; 17: 1713\u20131720.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016239_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/bmt.2014.7","volume":"49","author":"A Nagler","year":"2014","unstructured":"Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Soci\u00e9 G et al. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone Marrow Transplant 2014; 49: 628\u2013633.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016239_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1046\/j.1365-2141.2000.02202.x","volume":"110","author":"AM Wardley","year":"2000","unstructured":"Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110: 292\u2013299.","journal-title":"Br J Haematol"},{"key":"BFbmt2016239_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/annonc\/mdf052","volume":"13","author":"AD Huitema","year":"2002","unstructured":"Huitema AD, Spaander M, Math\u0135t RA, Tibben MM, Holtkamp MJ, Beijnen JH et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 2002; 13: 374\u2013384.","journal-title":"Ann Oncol"},{"key":"BFbmt2016239_CR31","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","volume":"23","author":"F Aversa","year":"2005","unstructured":"Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447\u20133454.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016239_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bcmd.2004.08.006","volume":"33","author":"I Walker","year":"2004","unstructured":"Walker I, Shehata N, Cantin G, Couture F, Dh\u00e9din N, Barty R et al. Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis 2004; 33: 222\u2013226.","journal-title":"Blood Cells Mol Dis"},{"key":"BFbmt2016239_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/ejh.12553","volume":"96","author":"S Eder","year":"2015","unstructured":"Eder S, Labopin M, Arcese W, Or R, Majolino I, Bacigalupo A et al. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Haematol 2015; 96: 90\u201397.","journal-title":"Eur J Haematol"},{"key":"BFbmt2016239_CR34","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen\u2014a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol 2013; 31: 3549\u20133556.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016239","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:08:22Z","timestamp":1648048102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,19]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFbmt2016239"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.239","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,19]]},"assertion":[{"value":"20 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM received lectures honoraria and research support from Riemser whose product is discussed in this work. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}